Biotech Meets Battlefield – De-Risking Defense Innovation and Supply Chains: BI Replay

U.S. national security leaders are betting big on biotechnology to resolve critical supply chain vulnerabilities and maintain technological superiority. With bipartisan support, the Department of Defense is moving to fund and scale innovations in bio-manufacturing — yet investors remain cautious around regulatory risks and commercialization hurdles. Join Wayne Sanders, Senior Analyst, Defense Weapons Systems, for a timely conversation with Dr. Doug Friedman, CEO, BioMADE, as they explore the funding flows, operational models, and strategic value of defense-aligned biotech manufacturing. From pilot-stage innovation to scaled deployment, this session will unpack how public-private collaboration is transforming the future of defense logistics.